Page 63 - Medication Guide News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) January 20, 2021 GMT KENILWORTH, N.J.--(BUSINESS WIRE)--Jan 20, 2021-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitaliza...

How to get Oxycodone price or Oxycodone for sale Read the Medication Guide provided by your health care provider before you start taking oxycodone and each time you get a refill. If you have any queries about Oxycodone price or Oxycodone for sale, feel free to connect oxyorintstore. Take this medication orally as directed by your doctor. You'll take this drug with or while not having food. If you've nausea, it should facilitate to need this drug with food. Raise your doctor or apothecary...

Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications - New analyses from CD-PROBE study evaluating sustained efficacy and tolerability of onabotulinumtoxinA in patients with cervical dystonia - New analyses from the ASPIRE study on patient adhe...

adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS). ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). It is not known if ULTOMIRIS is safe and effective in children with PNH. It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age. IMPORTANT SAFETY INFORMATION What is th...

Press release content from Business Wire. The AP news staff was not involved in its creation. Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 January 13, 2021 GMT BOSTON--(BUSINESS WIRE)--Jan 13, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the decision to pause further enrollment in the global Phase 3 study of ULTOMIRIS ® (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventila...

The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis PLEGRIDY is now approved in the European Union for intramuscular injection, offering individuals with relapsing multiple sclerosis (MS) a differentiated, reliable treatment option combining safety and efficacy to help optimize their treatment experience with significantly reduced injection site reactions The only pegylated interfer...

Managing life with MS during the pandemic Dec. 18, 2020 FacebookTwitterEmail (BPT) - Crystal is a wife, mother of four and a frontline healthcare worker who also happens to have multiple sclerosis (MS). Though she had experienced numbness, tingling and pain since she was a child, doctors initially downplayed her symptoms. It was not until 2003, while Crystal was in nursing school, that she received her MS diagnosis after she became unconscious and ended up in the emergency room, blind and paral...

Multiple Myeloma: Maintaining Hope While Navigating a Chronic Blood Cancer Dec. 18, 2020 FacebookTwitterEmail (BPT) - Tiffany Williams went to the doctor to see if something could be done about her severe back pain, but the root cause was something she wasnt planning on. She learned she had multiple myeloma. As the doctor explained this rare form of blood cancer and how it would impact her life, her brain latched on to a single phrase: “Incurable but treatable.” As the news settled in over ...

Hikma launches generic Advair Diskus® following FDA approval News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKlines Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. Hikma worked with Vectura Group, a UK ...

  London, 17 December  2020   - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, annou nces it has received FDA approval for and launched its generic version of GlaxoSmithKlines Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.   Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery soluti...